# APOA1

## Overview
The APOA1 gene encodes apolipoprotein A-I, a key protein component of high-density lipoprotein (HDL) in human plasma. Apolipoprotein A-I is primarily involved in lipid metabolism, particularly in the process of reverse cholesterol transport, where it facilitates the movement of cholesterol from peripheral tissues to the liver for excretion. This protein is characterized by its amphipathic α-helical structure, which allows it to interact dynamically with lipids and other proteins, playing a crucial role in HDL assembly and remodeling. As a cofactor for lecithin:cholesterol acyltransferase (LCAT), apolipoprotein A-I is essential for the maturation of HDL particles. Beyond its metabolic functions, apolipoprotein A-I also exhibits anti-inflammatory properties and is involved in modulating immune responses. Mutations in the APOA1 gene can lead to various hereditary conditions, including amyloidosis and cardiovascular diseases, underscoring its significance in human health (Mukhopadhyay2016Possible; Cochran2021APOA1:; Obici1999The).

## Structure
The APOA1 gene encodes apolipoprotein A-I, a major component of high-density lipoprotein (HDL) in plasma. The primary structure of apoA-I consists of 243 amino acids, with the first 43 residues encoded by exon 3 and the remaining 44-243 residues by exon 4 (Mei2011Crystal). The secondary structure is predominantly composed of amphipathic α-helices, with specific regions forming α-helical segments, such as residues 7-44, 54-65, 70-78, 81-115, and 147-178, contributing to a helical content of approximately 48% (Chetty2009Helical).

The tertiary structure of apoA-I involves a helix bundle, with the N-terminal domain (residues 1-189) being more structured and the C-terminal domain (residues 190-243) more flexible (Mei2011Crystal; Chetty2009Helical). The protein's structure is dynamic, allowing it to reorganize during HDL particle formation and remodeling (Chetty2009Helical).

In terms of quaternary structure, apoA-I can form dimers and higher-order oligomers. The dimerization involves five AB-repeating motifs, which serve as the major dimerization interface (Mei2011Crystal). The protein can adopt a "double belt" model when bound to discoidal HDL particles, wrapping around the lipid disc (Borhani1997Crystal). The flexible nature of apoA-I is crucial for its function in HDL assembly and cholesterol transport (Segrest2014An).

## Function
Apolipoprotein A1 (APOA1) is a critical component of high-density lipoprotein (HDL) in human plasma, playing a significant role in lipid metabolism and cardiovascular health. It is primarily involved in the process of reverse cholesterol transport, where it facilitates the efflux of cholesterol and phospholipids from peripheral tissues to the liver for excretion. This process is mediated by the ATP-binding cassette transporter A1 (ABCA1), which is essential for the formation of nascent HDL particles (Mukhopadhyay2016Possible; Cochran2021APOA1:).

APOA1 acts as a cofactor for lecithin:cholesterol acyltransferase (LCAT), an enzyme that catalyzes the esterification of free cholesterol, transforming discoidal HDL into spherical HDL, which is crucial for HDL maturation (Mukhopadhyay2016Possible). In addition to its role in lipid metabolism, APOA1 is involved in modulating inflammation. It can exert anti-inflammatory effects by inhibiting macrophage activation and reducing pro-inflammatory cytokine production through pathways involving ABCA1 and the JAK/STAT signaling pathway (Mukhopadhyay2016Possible; Cochran2021APOA1:).

APOA1 is also active in the central nervous system, where it aids in cholesterol removal from neurons and may play a role in neuronal regeneration and inflammation modulation (Mukhopadhyay2016Possible).

## Clinical Significance
Mutations in the APOA1 gene are associated with several hereditary conditions, primarily involving amyloidosis and cardiovascular diseases. Familial systemic amyloidosis, an autosomal dominant disorder, results from mutations in APOA1, leading to the deposition of amyloid fibrils in various organs, including the heart, liver, and kidneys. These fibrils are typically composed of N-terminal fragments of the apoA-I protein (Das2016Structural; Obici1999The). Specific mutations, such as the Leu174Ser and Arg173Pro, have been linked to hereditary cardiac amyloidosis, characterized by heart failure and other cardiac complications (Hamidi1999A; Obici1999The).

APOA1 mutations also contribute to HDL deficiency and increased risk of atherosclerotic cardiovascular disease (ASCVD). Patients with damaging mutations in APOA1 often exhibit low HDL-C levels and impaired cholesterol efflux capacity, which are associated with a higher prevalence of ASCVD (AbdelRazek2018Increased; Pisciotta2015A). Additionally, some mutations in APOA1 can lead to familial hypercholesterolemia, a condition characterized by elevated cholesterol levels and increased risk of cardiovascular events (Raimondi2011Effects). These mutations highlight the critical role of APOA1 in lipid metabolism and its impact on human health.

## Interactions
Apolipoprotein A1 (APOA1) is involved in several critical protein-protein interactions that facilitate its role in lipid metabolism and cardiovascular health. APOA1 forms dimers through interactions involving inter-helical salt bridges, such as Asp 89 -Arg 177 and Glu 111 -His 155, which are essential for the assembly of high-density lipoprotein (HDL) particles (Mei2011Crystal). These dimers are considered intermediate states in HDL assembly, undergoing structural rearrangements upon lipid binding to form discoidal HDL particles (Mei2011Crystal).

APOA1 interacts with lecithin-cholesterol acyltransferase (LCAT), activating this enzyme through specific residues like Arg 149 and Arg 153, which are crucial for converting nascent HDL into mature, cholesterol ester-rich HDL (Chistiakov2016ApoA1). It also interacts with the ATP-binding cassette transporter A1 (ABCA1) on macrophages, facilitating cholesterol efflux and inhibiting ABCA1 degradation (Cochran2021APOA1:).

In the context of inflammation, APOA1 interacts with serum amyloid A (SAA) and heparin, leading to the dissociation of these proteins from HDL in a concentration-dependent manner (Digre2016Heparin). These interactions suggest a role for APOA1 in modulating HDL function during inflammatory conditions.


## References


[1. (Borhani1997Crystal) David W. Borhani, Danise P. Rogers, Jeffrey A. Engler, and Christie G. Brouillette. Crystal structure of truncated human apolipoprotein a-i suggests a lipid-bound conformation. Proceedings of the National Academy of Sciences, 94(23):12291–12296, November 1997. URL: http://dx.doi.org/10.1073/pnas.94.23.12291, doi:10.1073/pnas.94.23.12291. This article has 363 citations.](https://doi.org/10.1073/pnas.94.23.12291)

[2. (Segrest2014An) Jere P. Segrest, Martin K. Jones, Baohai Shao, and Jay W. Heinecke. An experimentally robust model of monomeric apolipoprotein a-i created from a chimera of two x-ray structures and molecular dynamics simulations. Biochemistry, 53(48):7625–7640, November 2014. URL: http://dx.doi.org/10.1021/bi501111j, doi:10.1021/bi501111j. This article has 22 citations and is from a peer-reviewed journal.](https://doi.org/10.1021/bi501111j)

[3. (Raimondi2011Effects) Sara Raimondi, Fulvio Guglielmi, Sofia Giorgetti, Sonia Di Gaetano, Angela Arciello, Daria M. Monti, Annalisa Relini, Daniela Nichino, Silvia M. Doglia, Antonino Natalello, Piero Pucci, Palma Mangione, Laura Obici, Giampaolo Merlini, Monica Stoppini, Paul Robustelli, Gian Gaetano Tartaglia, Michele Vendruscolo, Christopher M. Dobson, Renata Piccoli, and Vittorio Bellotti. Effects of the known pathogenic mutations on the aggregation pathway of the amyloidogenic peptide of apolipoprotein a-i. Journal of Molecular Biology, 407(3):465–476, April 2011. URL: http://dx.doi.org/10.1016/j.jmb.2011.01.044, doi:10.1016/j.jmb.2011.01.044. This article has 47 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.jmb.2011.01.044)

[4. (Mukhopadhyay2016Possible) Debashis Mukhopadhyay. Possible role of apolipoprotein a1 in healing and cell death after neuronal injury. Frontiers in Bioscience, 8(3):460–477, 2016. URL: http://dx.doi.org/10.2741/e780, doi:10.2741/e780. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.2741/e780)

[5. (Chetty2009Helical) Palaniappan Sevugan Chetty, Leland Mayne, Sissel Lund-Katz, David Stranz, S. Walter Englander, and Michael C. Phillips. Helical structure and stability in human apolipoprotein a-i by hydrogen exchange and mass spectrometry. Proceedings of the National Academy of Sciences, 106(45):19005–19010, November 2009. URL: http://dx.doi.org/10.1073/pnas.0909708106, doi:10.1073/pnas.0909708106. This article has 135 citations.](https://doi.org/10.1073/pnas.0909708106)

[6. (Cochran2021APOA1:) Blake J. Cochran, Kwok-Leung Ong, Bikash Manandhar, and Kerry-Anne Rye. Apoa1: a protein with multiple therapeutic functions. Current Atherosclerosis Reports, February 2021. URL: http://dx.doi.org/10.1007/s11883-021-00906-7, doi:10.1007/s11883-021-00906-7. This article has 85 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s11883-021-00906-7)

[7. (AbdelRazek2018Increased) Omar Abdel-Razek, Singh N. Sadananda, Xuan Li, Lubomira Cermakova, Jiri Frohlich, and Liam R. Brunham. Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in abca1 or apoa1. Journal of Clinical Lipidology, 12(1):116–121, January 2018. URL: http://dx.doi.org/10.1016/j.jacl.2017.10.010, doi:10.1016/j.jacl.2017.10.010. This article has 26 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.jacl.2017.10.010)

[8. (Das2016Structural) Madhurima Das, Christopher J. Wilson, Xiaohu Mei, Thomas E. Wales, John R. Engen, and Olga Gursky. Structural stability and local dynamics in disease-causing mutants of human apolipoprotein a-i: what makes the protein amyloidogenic? Journal of Molecular Biology, 428(2):449–462, January 2016. URL: http://dx.doi.org/10.1016/j.jmb.2015.10.029, doi:10.1016/j.jmb.2015.10.029. This article has 44 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.jmb.2015.10.029)

[9. (Hamidi1999A) Kamran Hamidi Asl, Juris J. Liepnieks, Masaaki Nakamura, Frank Parker, and Merrill D. Benson. A novel apolipoprotein a-1 variant, arg173pro, associated with cardiac and cutaneous amyloidosis. Biochemical and Biophysical Research Communications, 257(2):584–588, April 1999. URL: http://dx.doi.org/10.1006/bbrc.1999.0518, doi:10.1006/bbrc.1999.0518. This article has 77 citations and is from a peer-reviewed journal.](https://doi.org/10.1006/bbrc.1999.0518)

[10. (Pisciotta2015A) Livia Pisciotta, Cecilia Vitali, Elda Favari, Paola Fossa, Maria Pia Adorni, Daniela Leone, Nathan Artom, Raffaele Fresa, Laura Calabresi, Sebastiano Calandra, and Stefano Bertolini. A complex phenotype in a child with familial hdl deficiency due to a novel frameshift mutation in apoa1 gene (apoa-i guastalla ). Journal of Clinical Lipidology, 9(6):837–846, November 2015. URL: http://dx.doi.org/10.1016/j.jacl.2015.09.001, doi:10.1016/j.jacl.2015.09.001. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.jacl.2015.09.001)

[11. (Mei2011Crystal) Xiaohu Mei and David Atkinson. Crystal structure of c-terminal truncated apolipoprotein a-i reveals the assembly of high density lipoprotein (hdl) by dimerization. Journal of Biological Chemistry, 286(44):38570–38582, November 2011. URL: http://dx.doi.org/10.1074/jbc.m111.260422, doi:10.1074/jbc.m111.260422. This article has 168 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m111.260422)

[12. (Digre2016Heparin) Andreas Digre, Jie Nan, Martin Frank, and Jin-Ping Li. Heparin interactions with apoa1 and saa in inflammation-associated hdl. Biochemical and Biophysical Research Communications, 474(2):309–314, May 2016. URL: http://dx.doi.org/10.1016/j.bbrc.2016.04.092, doi:10.1016/j.bbrc.2016.04.092. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2016.04.092)

[13. (Obici1999The) Laura Obici, Vittorio Bellotti, Palma Mangione, Monica Stoppini, Eloisa Arbustini, Laura Verga, Irene Zorzoli, Ernesto Anesi, Giuseppe Zanotti, Carlo Campana, Mario Viganò, and Giampaolo Merlini. The new apolipoprotein a-i variant leu174 → ser causes hereditary cardiac amyloidosis, and the amyloid fibrils are constituted by the 93-residue n-terminal polypeptide. The American Journal of Pathology, 155(3):695–702, September 1999. URL: http://dx.doi.org/10.1016/s0002-9440(10)65167-x, doi:10.1016/s0002-9440(10)65167-x. This article has 99 citations.](https://doi.org/10.1016/s0002-9440(10)65167-x)

[14. (Chistiakov2016ApoA1) Dimitry A Chistiakov, Alexander N Orekhov, and Yuri V Bobryshev. Apoa1 and apoa1-specific self-antibodies in cardiovascular disease. Laboratory Investigation, 96(7):708–718, July 2016. URL: http://dx.doi.org/10.1038/labinvest.2016.56, doi:10.1038/labinvest.2016.56. This article has 63 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/labinvest.2016.56)